Thermo Fisher Scientific closed at $698.34 on Nov 3, up 2.30%, 1.5% below its 52-week closing high. Volume of 1.7M shares was 0.70× its 20-day average (below normal).
Split-adjusted performance: +3.2% over one month, +49.6% over six months, +23.1% over one year.
In the quarter ended Sep 26, 2026, revenue was $12.14B, up 9.1% from a year earlier, with a net margin of 14.2%.
Short interest was 4.9M shares at the Oct 15 settlement, down 9.6% from the prior report (1.3% of float, 2.1 days to cover).